• Explore /
  • Poster
  • / Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Abstract Video & Slides Poster

Authors

null

Marwan Fakih

City of Hope National Medical Center, Duarte, CA

Marwan Fakih , Kanwal Pratap Singh Raghav , David Z. Chang , Timothy Larson , Allen Lee Cohn , Timothy K. Huyck , David Cosgrove , Joseph A. Fiorillo , David R. D'Adamo , Amy Hammell , Neelesh Sharma , Sabine Coppieters , Anke Schulz , Henrik Seidel , Matthias Herpers , Carolina Soares Viana de Oliveira , Andrew Scott Paulson , Ying A. Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04126733

DOI

10.1200/JCO.2022.40.4_suppl.089

Abstract #

89

Poster Bd #

E2

Abstract Disclosures

Similar Posters

First Author: Angela Damato

First Author: Anne Hansen Ree

First Author: Marwan Fakih

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.

Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.

First Author: Ibrahim Halil Sahin